These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
325 related articles for article (PubMed ID: 34779873)
1. Prognostic value of total metabolic tumour volume and therapy-response assessment by [ Annovazzi A; Ferraresi V; Rea S; Russillo M; Renna D; Carpano S; Sciuto R Eur Radiol; 2022 May; 32(5):3398-3407. PubMed ID: 34779873 [TBL] [Abstract][Full Text] [Related]
2. Correlation between early 18F-FDG PET/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanoma. Schmitt RJ; Kreidler SM; Glueck DH; Amaria RN; Gonzalez R; Lewis K; Bagrosky BM; Kwak JJ; Koo PJ Nucl Med Commun; 2016 Feb; 37(2):122-8. PubMed ID: 26440571 [TBL] [Abstract][Full Text] [Related]
3. The Predictive Value of FDG PET/CT for Determining Progression-Free Survival in Advanced Stage III-IV BRAF -Mutated Melanoma Patients Treated With Targeted Therapy-What Can Be Learned From Progression? van der Hiel B; Aalbersberg EA; van den Eertwegh AJM; de Wit-van der Veen LJ; Stokkel MPM; Lopez-Yurda M; Boellaard R; Kapiteijn EW; Hospers GAP; Aarts MJB; de Vos FYFL; Boers-Sonderen MJ; van der Veldt AAM; de Groot JWB; Haanen JBAG Clin Nucl Med; 2024 Feb; 49(2):138-145. PubMed ID: 38113329 [TBL] [Abstract][Full Text] [Related]
11. Prognostic Values of Baseline Zhou Y; Zhang X; Qin H; Zhao Z; Li J; Zhang B; Sang S; Wu Y; Deng S Biomed Res Int; 2020; 2020():9746716. PubMed ID: 32185229 [TBL] [Abstract][Full Text] [Related]
12. Total metabolic tumor volume on Tricarico P; Chardin D; Martin N; Contu S; Hugonnet F; Otto J; Humbert O J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38649279 [TBL] [Abstract][Full Text] [Related]
13. Ito K; Teng R; Schöder H; Humm JL; Ni A; Michaud L; Nakajima R; Yamashita R; Wolchok JD; Weber WA J Nucl Med; 2019 Mar; 60(3):335-341. PubMed ID: 30413661 [TBL] [Abstract][Full Text] [Related]
14. The role of interim Sachpekidis C; Anwar H; Winkler J; Kopp-Schneider A; Larribere L; Haberkorn U; Hassel JC; Dimitrakopoulou-Strauss A Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1289-1296. PubMed ID: 29478079 [TBL] [Abstract][Full Text] [Related]
15. (18)F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma. Carlino MS; Saunders CA; Haydu LE; Menzies AM; Martin Curtis C; Lebowitz PF; Kefford RF; Long GV Eur J Cancer; 2013 Jan; 49(2):395-402. PubMed ID: 22981500 [TBL] [Abstract][Full Text] [Related]
16. Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4. Seban RD; Moya-Plana A; Antonios L; Yeh R; Marabelle A; Deutsch E; Schwartz LH; Gómez RGH; Saenger Y; Robert C; Ammari S; Dercle L Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2301-2312. PubMed ID: 32206839 [TBL] [Abstract][Full Text] [Related]
17. Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma. Toledano MN; Desbordes P; Banjar A; Gardin I; Vera P; Ruminy P; Jardin F; Tilly H; Becker S Eur J Nucl Med Mol Imaging; 2018 May; 45(5):680-688. PubMed ID: 29344718 [TBL] [Abstract][Full Text] [Related]
18. Metabolic tumor burden on baseline Chen S; He K; Feng F; Wang S; Yin Y; Fu H; Wang H Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1830-1839. PubMed ID: 31187163 [TBL] [Abstract][Full Text] [Related]
19. Prognostic value of Geng H; Lian K; Zhang W Quant Imaging Med Surg; 2024 Jan; 14(1):325-334. PubMed ID: 38223089 [TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of integrating total metabolic tumor volume and EGFR mutation status in patients with lung adenocarcinoma. Jiang M; Guo X; Chen P; Zhang X; Gao Q; Zhang J; Zheng J PeerJ; 2024; 12():e16807. PubMed ID: 38250731 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]